Fibroma medical therapy
Jump to navigation
Jump to search
|
Fibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fibroma medical therapy On the Web |
|
American Roentgen Ray Society Images of Fibroma medical therapy |
|
Risk calculators and risk factors for Fibroma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2]
overview
The majority treatment of cases of fibromas is not medical therapy, but for some one's such as uterine fibroma does have medical therapy.Medical therapy depends on the type of fibroma.
Medical therapy
The majority treatment of cases of fibromas is not medical therapy, but for some one's such as uterine fibroma does have medical therapy.[1][2][3][4][5][6][7][8]
Uterine fibroma
- At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.[1][2][3][4][5][6][7][8]
Gonadotropin-Releasing Hormone Analogues
- Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause.
- Some of them are Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin
- Effects of GnRH agonists are temporary, and re-growth has been reported in many cases of leiomyomas to their pretreatment sizes after stopping them.
GnRH analogues With Add-Back Therapy
- Commonly used add-back agents are progestins alone, estrogen alone, combined estrogen and progesterone, tibolone, and raloxifene.
- To overcome the unwanted side effects and maintaining the benefits of GnRH therapy add-back therapy is commonly used.
References
- ↑ 1.0 1.1 Sabry, Mohamed; Al-Hendy, Ayman (2012). "Medical Treatment of Uterine Leiomyoma". Reproductive Sciences. 19 (4): 339–353. doi:10.1177/1933719111432867. ISSN 1933-7191.
- ↑ 2.0 2.1 Donnez, Jacques; Dolmans, Marie-Madeleine (2016). "Uterine fibroid management: from the present to the future". Human Reproduction Update. 22 (6): 665–686. doi:10.1093/humupd/dmw023. ISSN 1355-4786.
- ↑ 3.0 3.1 Murji, Ally; Whitaker, Lucy; Chow, Tiffany L; Sobel, Mara L (2017). "Selective progesterone receptor modulators (SPRMs) for uterine fibroids". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010770.pub2. ISSN 1465-1858.
- ↑ 4.0 4.1 Arena, Saverio; Zupi, Errico (2011). "Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option". Women's Health. 7 (2): 143–146. doi:10.2217/WHE.11.1. ISSN 1745-5065.
- ↑ 5.0 5.1 De Leo, Vincenzo; Morgante, Giuseppe; La Marca, Antonio; Musacchio, Maria Concetta; Sorace, Massimo; Cavicchioli, Chiara; Petraglia, Felice (2002). "A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas". Drug Safety. 25 (11): 759–779. doi:10.2165/00002018-200225110-00002. ISSN 0114-5916.
- ↑ 6.0 6.1 Sankaran, Srividhya; Manyonda, Isaac T. (2008). "Medical management of fibroids". Best Practice & Research Clinical Obstetrics & Gynaecology. 22 (4): 655–676. doi:10.1016/j.bpobgyn.2008.03.001. ISSN 1521-6934.
- ↑ 7.0 7.1 Palomba, S. (2002). "Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial". Human Reproduction. 17 (12): 3213–3219. doi:10.1093/humrep/17.12.3213. ISSN 1460-2350.
- ↑ 8.0 8.1 Golan, A. (1996). "GnRH analogues in the treatment of uterine fibroids". Human Reproduction. 11 (suppl 3): 33–41. doi:10.1093/humrep/11.suppl_3.33. ISSN 0268-1161.